<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Merck (MRK) Gains Breakthrough Therapy Designation For Lung Cancer Drug — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Merck (MRK) Gains Breakthrough Therapy Designation For Lung Cancer Drug</h2>
    <div class="badge">2025-09-08T17:28:09+00:00</div>
    <ul>
      <li>Analysts predict a revenue growth rate of 4.2% per annum over the next few years.</li>
<li>Given the current share price of US$84.71, the analyst consensus price target sits at US$101.75, representing a 20.8% potential upside.</li>
<li>The immediate impact has been a share price boost of 4.98% last month.</li>
<li>Over a five-year period, Merck’s total shareholder return, including share price and dividends, increased by 22.43%.</li>
<li>However, in the last year, the company underperformed compared to the US Pharmaceuticals industry, which returned 11.5%.</li>
<li>Merck recently presented promising phase 2 trial results for ifinatamab deruxtecan, earning Breakthrough Therapy Designation from multiple regulatory bodies, an event that coincides with the company&#x27;s 4.98% share price i</li>
<li>We&#x27;ve identified 1 weakness for Merck that you should be aware of.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=Merck%20%28MRK%29%20Gains%20Breakthrough%20Therapy%20Designation%20For%20Lung%20Cancer%20Drug%0A%E2%80%A2%20Analysts%20predict%20a%20revenue%20growth%20rate%20of%204.2%25%20per%20annum%20over%20the%20next%20few%20years.%0A%E2%80%A2%20Given%20the%20current%20share%20price%20of%20US%2484.71%2C%20the%20analyst%20consensus%20price%20target%20sits%20at%20US%24101.75%2C%20representing%20a%2020.8%25%20potential%20upside.%0A%E2%80%A2%20The%20immediate%20impact%20has%20been%20a%20share%20price%20boost%20of%204.98%25%20last%20month.%0A%E2%80%A2%20Over%20a%20five-year%20period%2C%20Merck%E2%80%99s%20total%20shareholder%20return%2C%20including%20share%20price%20and%20dividends%2C%20increased%20by%2022.43%25.%0A%E2%80%A2%20However%2C%20in%20the%20last%20year%2C%20the%20company%20underperformed%20compared%20to%20the%20US%20Pharmaceuticals%20industry%2C%20which%20returned%2011.5%25.%0A%E2%80%A2%20Merck%20recently%20presented%20promising%20phase%202%20trial%20results%20for%20ifinatamab%20deruxtecan%2C%20earning%20Breakthrough%20Therapy%20Designation%20from%20multiple%20regulatory%20bodies%2C%20an%20event%20that%20coincides%20with%20the%20company%27s%204.98%25%20share%20price%20i%0A%E2%80%A2%20We%27ve%20identified%201%20weakness%20for%20Merck%20that%20you%20should%20be%20aware%20of.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fmerck-mrk-gains-breakthrough-therapy-designation-for-lung-cancer-drug%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/merck-mrk-gains-breakthrough-therapy-172809106.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>